Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Lymphoma Cells
100%
Lymphoma
100%
Signal Transduction Inhibitors
100%
Inhibitor Therapy
100%
Chemotherapy Agents
80%
Non-Hodgkin Lymphoma
80%
Phosphatidylinositol 3-kinase/Akt
80%
Akt-mTOR Pathway
80%
Hodgkin Disease
80%
Clinical Trials
60%
RAF Kinase
60%
In Vitro Study
40%
Conventional Chemotherapy
40%
New Agents
40%
Malignant B Cells
40%
Patient Survival
40%
Pathway Inhibitors
40%
Phosphatidylinositol 3-kinase Pathway
40%
Lymphoma Treatment
40%
Farnesyltransferase
20%
Target Pathways
20%
Mechanism of Action
20%
NCCTG
20%
Novel Combinations
20%
Treatment Advances
20%
Cell Growth
20%
Lay Language
20%
Tipifarnib
20%
Large Cell
20%
Primary Tumor Cells
20%
Kinase Cascade
20%
Large-scale Testing
20%
New Drugs
20%
Response Rate
20%
New Combination
20%
Agent Behavior
20%
Signal Transduction Pathway
20%
Malignancy
20%
Clinical Activity
20%
Everolimus
20%
Phosphoinositide 3-kinase (PI3K)
20%
In(III)
20%
Action-based
20%
Unique Mechanism
20%
Rational Combinations
20%
Kinase Inhibitor
20%
Indolent non-Hodgkin Lymphoma
20%
Cooperative Group
20%
Specific Aims
20%
Antitumor Efficacy
20%
Sorafenib
20%
Temsirolimus
20%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphatidylinositol 3 Kinase
100%
Nonhodgkin Lymphoma
71%
Protein Kinase B
57%
Hodgkin Disease
57%
Chemotherapy Agent
57%
Clinical Trial
42%
Raf Protein
42%
Temsirolimus
14%
Sorafenib
14%
Everolimus
14%
Tipifarnib
14%
Primary Tumor
14%
Phosphotransferase Inhibitor
14%
Neoplasm
14%
Biological Marker
14%
Diseases
14%
Transferase
14%